5 Crucial Lessons for Healthcare Startups from BioticsAI’s Journey

Breaking into healthcare is notoriously difficult—especially when you’re building AI-powered solutions that require FDA clearance. Robhy Bustami, co-founder and CEO of BioticsAI, recently shared his hard-won insights on Build Mode, covering everything from regulatory hurdles to keeping his team motivated. Here are five key takeaways every healthtech founder should know.

1. Navigating the FDA Maze: Start Early and Stay Persistent

Securing FDA approval isn’t a one-time event—it’s an ongoing process that begins long before you submit an application. Bustami emphasizes that regulatory strategy must be baked into your product design from day one. BioticsAI’s team invested heavily in understanding FDA requirements upfront, which saved them months of rework later. They also learned to expect multiple rounds of feedback and rejection. The key is to treat the FDA as a partner, not an adversary, and to build a culture of documentation and compliance. Without this mindset, even the best technology can stall in the regulatory pipeline.

2. Fundraising When the Stakes Are High: Tell a Clear Story

Raising capital for a healthcare AI startup is different from typical tech fundraising. Investors want to see a clear path to revenue, regulatory milestones, and clinical validation. Bustami advises founders to focus on storytelling that connects the technology to tangible patient outcomes. BioticsAI succeeded by demonstrating early pilot studies and showing how their solution reduces physician burnout. He also warns against overpromising: investors in healthcare are risk-averse, so realistic timelines and honest assessments of regulatory risk build trust. Finally, don’t underestimate the importance of networking—many of BioticsAI’s key investors came through warm introductions from advisors.

3. Keeping Your Team Motivated Through Red Tape

Healthcare startups often face months of slow progress due to audits, paperwork, and waiting for regulatory decisions. Bustami notes that motivation can wane when the finish line seems far away. His solution is to celebrate small wins—like completing a successful audit or getting a positive FDA meeting—and to constantly reinforce the mission: improving patient care. He also recommends creating a transparent culture where team members understand why the red tape exists and how their work fits into the bigger picture. Regular all-hands meetings and open discussions about challenges help the team feel invested in the journey.

4. The Realities of Building in a Regulated Space

Building a product in healthcare means accepting that speed will always be limited by safety and compliance. Bustami points out that every feature change or algorithm update can trigger a new regulatory review. BioticsAI had to redesign their software architecture to allow for easier updates without breaking FDA compliance. He also warns against the temptation to cut corners—one misstep can destroy years of work. The reality is that healthcare startups need deeper pockets, longer timelines, and more patient investors than almost any other sector. But the payoff, he says, is a defensible business with high barriers to entry.

5. Strategies for Cutting Through Bureaucracy

To avoid being suffocated by paperwork, Bustami recommends automating compliance wherever possible. BioticsAI built internal tools to track regulatory submissions and manage documentation. They also hired a dedicated regulatory affairs specialist early on, which freed up engineers to focus on product development. Another tactic is to engage with regulators informally—attending FDA workshops or participating in pilot programs—so that when you do submit, you’re not starting from scratch. Finally, he advises choosing your battles: sometimes it’s faster to work within existing frameworks than to try to invent new ones.

These lessons from BioticsAI’s journey highlight that success in healthcare tech requires a unique blend of technical excellence, regulatory savvy, and resilient leadership. While the road is long, the impact—and the market opportunity—makes it worthwhile for those who can navigate the maze.